https://mindmedicinelaw.com/briefing/nmda-receptors-and-lhb-burst-firing-new-insights-20260611-12241The Psychedelic Journalen2026-06-12T15:06:43.198881+00:00NMDA Receptors and LHb Burst Firing: New InsightsNMDA receptors, lateral habenula, burst firing, depression treatment, ketamine, neuroscience research, antidepressants, NMDAR antagonists, neural mechanisms, clinical implicationshttps://mindmedicinelaw.com/briefing/neurobiology-of-depression-anxiety-implications-for-psychedelic-research-20260611-12242The Psychedelic Journalen2026-06-12T15:06:33.136539+00:00Neurobiology of Depression & Anxiety: Implications for Psychedelic Researchneurobiology of depression, anxiety disorders, psychedelic therapies, neurotransmitter systems, neural circuitry, precision psychiatry, neuroinflammation, genetic influences, HPA axis dysfunctionhttps://mindmedicinelaw.com/briefing/biopsychosocial-framework-for-addiction-implications-for-psychedelic-therapies-20260611-12192The Psychedelic Journalen2026-06-12T15:06:23.533065+00:00Biopsychosocial Framework for Addiction: Implications for Psychedelic Therapiesbiopsychosocial framework, addiction models, psychedelic-assisted therapy, neuroscience, public health, clinical trials, psychosocial factors, addiction treatment, multidimensional approach, emerging interventionshttps://mindmedicinelaw.com/briefing/telehealth-ketamine-for-depression-review-insights-20260611-12297The Psychedelic Journalen2026-06-12T15:05:52.199248+00:00Telehealth Ketamine for Depression: Review Insightstelehealth ketamine, depression treatment, anxiety treatment, psychedelic-assisted therapy, mental health care, systematic review, telemedicine, NMDA receptor antagonisthttps://mindmedicinelaw.com/briefing/colorado-s-ibogaine-law-and-its-impact-on-psilocybin-regulation-20260611-11993The Psychedelic Journalen2026-06-11T15:03:54.910697+00:00Colorado's Ibogaine Law and Its Impact on Psilocybin Regulationcolorado ibogaine law, psilocybin regulation, psychedelic substances, unlicensed sales, market dynamics, legal compliancehttps://mindmedicinelaw.com/briefing/predictive-brain-scans-for-adolescent-depression-a-new-frontier-20260610-12194The Psychedelic Journalen2026-06-12T22:04:32.402748+00:00Predictive Brain Scans for Adolescent Depression: A New Frontieradolescent depression, fMRI scan, predictive marker, mental health, early intervention, neuroimaging, brain dynamics, clinical validation, public health, mental health policyhttps://mindmedicinelaw.com/briefing/clozapine-s-impact-on-brain-structure-in-schizophrenia-20260610-12197The Psychedelic Journalen2026-06-12T22:04:24.862290+00:00Clozapine's Impact on Brain Structure in Schizophreniaclozapine, schizophrenia, brain structure, serotonergic receptors, cortical thinning, grey matter volumehttps://mindmedicinelaw.com/briefing/self-transcendence-in-moral-injury-recovery-clinical-implications-20260610-12036The Psychedelic Journalen2026-06-12T22:04:16.594536+00:00Self-Transcendence in Moral Injury Recovery: Clinical Implicationsmoral injury, self-transcendence, mindfulness, cognitive flexibility, clinical interventions, neuroscience, psychological recovery, contemplative practiceshttps://mindmedicinelaw.com/briefing/survey-reveals-variability-in-ketamine-assisted-psychotherapy-20260610-12229The Psychedelic Journalen2026-06-12T15:06:03.746754+00:00Survey Reveals Variability in Ketamine-Assisted Psychotherapyketamine-assisted psychotherapy, depression treatment, psychedelic therapy, clinical trials, psychotherapy modalities, neuroplasticity, evidence-based standardshttps://mindmedicinelaw.com/briefing/breathwork-s-potential-in-inducing-altered-states-of-consciousness-20260610-12037The Psychedelic Journalen2026-06-11T22:05:34.522123+00:00Breathwork's Potential in Inducing Altered States of Consciousnessbreathwork, altered states of consciousness, psychedelics, therapeutic applications, non-pharmacological interventions, mental health, clinical trials, emotional breakthroughs, consciousness research, psychological insightshttps://mindmedicinelaw.com/briefing/molecular-features-in-lewy-body-dementia-cortical-atrophy-20260610-12070The Psychedelic Journalen2026-06-11T22:05:22.585307+00:00Molecular Features in Lewy Body Dementia Cortical Atrophylewy body dementia, cortical atrophy, molecular pathways, neurodegenerative research, clinical trials, GABAergic signaling, mitochondrial function, synaptic transmission, Parkinson's disease, Alzheimer's diseasehttps://mindmedicinelaw.com/briefing/machine-learning-enhances-autism-mouse-model-profiling-20260610-12071The Psychedelic Journalen2026-06-11T22:05:13.731133+00:00Machine Learning Enhances Autism Mouse Model Profilingmachine learning, autism spectrum disorder, behavioral profiling, genetic mouse models, psychedelic research, neurodevelopmental disorders, Shank3B knockout mice, phenotype detection, translational studies, therapeutic interventionshttps://mindmedicinelaw.com/briefing/patient-views-on-psychedelic-therapy-for-aud-insights-and-implications-20260610-12035The Psychedelic Journalen2026-06-11T22:04:58.061715+00:00Patient Views on Psychedelic Therapy for AUD: Insights and Implicationsalcohol use disorder, psychedelic therapy, patient perceptions, clinical trials, informed consent, treatment expectations, addiction treatment, ethical researchhttps://mindmedicinelaw.com/briefing/ethical-challenges-in-ketamine-therapy-in-norway-20260610-12082The Psychedelic Journalen2026-06-11T22:04:44.912073+00:00Ethical Challenges in Ketamine Therapy in Norwayketamine-assisted psychotherapy, ethical challenges, Norway, treatment-resistant depression, informed consent, therapeutic integrity, access to care, psychedelic therapies, principlist bioethics, health policyhttps://mindmedicinelaw.com/briefing/optimi-health-ships-psilocybin-to-uk-for-clinical-trials-20260610-11992The Psychedelic Journalen2026-06-11T15:04:04.628301+00:00Optimi Health Ships Psilocybin to UK for Clinical Trialsoptimi health, psilocybin shipment, clinical trials, international collaboration, psychedelic research, UK regulatory framework, therapeutic potential, cross-border supply, controlled substances, regulatory approvalshttps://mindmedicinelaw.com/briefing/fluoxetine-and-astrocytic-camp-new-insights-in-ssri-mechanisms-20260608-12084The Psychedelic Journalen2026-06-12T22:04:52.561727+00:00Fluoxetine and Astrocytic cAMP: New Insights in SSRI Mechanismsfluoxetine, astrocytic cAMP, SSRIs, purinergic signalling, antidepressant therapy, glial cells, astrocytes, microglia, depression, neurosciencehttps://mindmedicinelaw.com/briefing/interpersonal-grounding-in-psilocybin-therapy-clinical-insights-20260608-12076The Psychedelic Journalen2026-06-12T22:04:43.982964+00:00Interpersonal Grounding in Psilocybin Therapy: Clinical Insightspsilocybin therapy, interpersonal grounding, therapist-participant relationship, psychedelic-assisted therapy, clinical trials, therapeutic models, mental health treatment, psychedelic research, therapeutic frameworks, therapy outcomeshttps://mindmedicinelaw.com/briefing/psychedelics-structure-activity-therapeutic-implications-20260608-12137The Psychedelic Journalen2026-06-11T22:05:05.400544+00:00Psychedelics: Structure-Activity & Therapeutic Implicationspsychedelic pharmacology, structure-activity relationships, neuropsychiatric disorders, clinical trial design, mental health treatment, psychedelic therapyhttps://mindmedicinelaw.com/briefing/psychedelics-in-palliative-care-new-evaluation-published-20260602-12301The Psychedelic Journalen2026-06-12T15:06:13.851356+00:00Psychedelics in Palliative Care: New Evaluation Publishedpsychedelics, palliative care, end-of-life care, psilocybin, MDMA, clinical trials, patient well-being, policy implications, therapeutic use, psychoactive substanceshttps://mindmedicinelaw.com/briefing/psychedelics-influence-on-personality-updated-insights-20260531-11656The Psychedelic Journalen2026-06-11T15:04:13.161108+00:00Psychedelics' Influence on Personality: Updated Insightspsychedelics, personality traits, systematic review, therapeutic applications, individual variability, serotonin receptors, clinical trials